• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

基于调节性 T 细胞的疗法在重症 COVID-19 治疗中的潜力。

Potential of regulatory T-cell-based therapies in the management of severe COVID-19.

机构信息

Division of Immunology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA.

Institut National de la Santé et de la Recherche Médicale; Centre de Recherche des Cordeliers, Sorbonne Université, Université de Paris, Paris, France.

出版信息

Eur Respir J. 2020 Sep 3;56(3). doi: 10.1183/13993003.02182-2020. Print 2020 Sep.

DOI:10.1183/13993003.02182-2020
PMID:32616599
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7331657/
Abstract

https://bit.ly/3eKqWPo

摘要

https://bit.ly/3eKqWPo

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7b16/7331657/ecd646f27660/ERJ-02182-2020.01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7b16/7331657/ecd646f27660/ERJ-02182-2020.01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7b16/7331657/ecd646f27660/ERJ-02182-2020.01.jpg

相似文献

1
Potential of regulatory T-cell-based therapies in the management of severe COVID-19.基于调节性 T 细胞的疗法在重症 COVID-19 治疗中的潜力。
Eur Respir J. 2020 Sep 3;56(3). doi: 10.1183/13993003.02182-2020. Print 2020 Sep.
2
A hundred days into the coronavirus disease (COVID-19) pandemic.新型冠状病毒肺炎（COVID-19）疫情爆发一百天之际。
Euro Surveill. 2020 Apr;25(14). doi: 10.2807/1560-7917.ES.2020.25.14.2000550.
3
Importing coronavirus disease 2019 (COVID-19) into China after international air travel.国际航空旅行后将2019冠状病毒病（COVID-19）输入中国。
Travel Med Infect Dis. 2020 May-Jun;35:101620. doi: 10.1016/j.tmaid.2020.101620. Epub 2020 Mar 25.
4
The clinical characteristics of myocardial injury in severe and very severe patients with 2019 novel coronavirus disease.2019新型冠状病毒病重症和危重症患者心肌损伤的临床特征
J Infect. 2020 Jul;81(1):147-178. doi: 10.1016/j.jinf.2020.03.021. Epub 2020 Mar 21.
5
COVID-19 Outbreak Associated with Air Conditioning in Restaurant, Guangzhou, China, 2020.2020年中国广州某餐厅与空调相关的新型冠状病毒肺炎疫情
Emerg Infect Dis. 2020 Sep;26(9):2298. doi: 10.3201/eid2609.201749. Epub 2020 Jun 24.
6
China empowers Internet hospital to fight against COVID-19.中国赋予互联网医院抗击新冠疫情的能力。
J Infect. 2020 Jul;81(1):e67-e68. doi: 10.1016/j.jinf.2020.03.061. Epub 2020 Apr 3.
7
Tumor biomarkers predict clinical outcome of COVID-19 patients.肿瘤生物标志物可预测新冠病毒肺炎患者的临床结局。
J Infect. 2020 Sep;81(3):452-482. doi: 10.1016/j.jinf.2020.05.069. Epub 2020 Jun 11.
8
Children hospitalized for coronavirus disease 2019 (COVID-19): A multicenter retrospective descriptive study.因2019冠状病毒病（COVID-19）住院的儿童：一项多中心回顾性描述性研究。
J Infect. 2020 Aug;81(2):e74-e75. doi: 10.1016/j.jinf.2020.04.045. Epub 2020 May 7.
9
IL-6 may be a good biomarker for earlier detection of COVID-19 progression.白细胞介素-6可能是早期检测新型冠状病毒肺炎病情进展的良好生物标志物。
Intensive Care Med. 2020 Jul;46(7):1475-1476. doi: 10.1007/s00134-020-06065-8. Epub 2020 May 8.
10
Rhabdomyolysis as Potential Late Complication Associated with COVID-19.横纹肌溶解症作为与2019冠状病毒病相关的潜在晚期并发症
Emerg Infect Dis. 2020 Oct;26(10):2535. doi: 10.3201/eid2610.202225. Epub 2020 Jul 2.

引用本文的文献

1
Other Immunomodulatory Treatment for Cytokine Storm Syndromes.其他细胞因子风暴综合征的免疫调节治疗。
Adv Exp Med Biol. 2024;1448:601-609. doi: 10.1007/978-3-031-59815-9_40.
2
IL-13 decreases susceptibility to airway epithelial SARS-CoV-2 infection but increases disease severity in vivo.白细胞介素-13降低气道上皮细胞对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）感染的易感性，但在体内会增加疾病严重程度。
bioRxiv. 2024 Jul 4:2024.07.03.601941. doi: 10.1101/2024.07.03.601941.
3
Harnessing immunity: Immunomodulatory therapies in COVID-19.利用免疫：COVID-19中的免疫调节疗法。

本文引用的文献

1
Hospital admissions in inflammatory rheumatic diseases during the peak of COVID-19 pandemic: incidence and role of disease-modifying agents.新冠疫情高峰期间炎性风湿性疾病的住院情况：改善病情药物的发病率及作用
Ther Adv Musculoskelet Dis. 2021 Feb 4;13:1759720X20962692. doi: 10.1177/1759720X20962692. eCollection 2021.
2
T-Cell Hyperactivation and Paralysis in Severe COVID-19 Infection Revealed by Single-Cell Analysis.单细胞分析揭示严重 COVID-19 感染中的 T 细胞过度激活和瘫痪。
Front Immunol. 2020 Oct 8;11:589380. doi: 10.3389/fimmu.2020.589380. eCollection 2020.
3
Regulatory T Cells for Treating Patients With COVID-19 and Acute Respiratory Distress Syndrome: Two Case Reports.
World J Virol. 2024 Jun 25;13(2):92521. doi: 10.5501/wjv.v13.i2.92521.
4
Association Between Altered Microbiota Composition and Immune System-Related Genes in COVID-19 Infection.新型冠状病毒肺炎感染中微生物群组成改变与免疫系统相关基因之间的关联
Mol Biotechnol. 2025 Mar;67(3):957-973. doi: 10.1007/s12033-024-01096-8. Epub 2024 Mar 8.
5
A comprehensive review on pharmacologic agents, immunotherapies and supportive therapeutics for COVID-19.关于COVID-19的药物制剂、免疫疗法和支持性疗法的全面综述。
Narra J. 2022 Dec;2(3):e92. doi: 10.52225/narra.v2i3.92. Epub 2022 Dec 8.
6
Next-generation treatments: Immunotherapy and advanced therapies for COVID-19.下一代治疗方法：针对新冠病毒的免疫疗法和先进疗法。
Heliyon. 2024 Feb 19;10(5):e26423. doi: 10.1016/j.heliyon.2024.e26423. eCollection 2024 Mar 15.
7
Oxidative stress-initiated one-carbon metabolism drives the generation of interleukin-10-producing B cells to resolve pneumonia.氧化应激引发的一碳代谢驱动产生白细胞介素-10 的 B 细胞以解决肺炎。
Cell Mol Immunol. 2024 Jan;21(1):19-32. doi: 10.1038/s41423-023-01109-7. Epub 2023 Dec 11.
8
Increased blood immune regulatory cells in severe COVID-19 with autoantibodies to type I interferons.严重 COVID-19 患者血液中免疫调节细胞增加，伴有针对 I 型干扰素的自身抗体。
Sci Rep. 2023 Oct 13;13(1):17344. doi: 10.1038/s41598-023-43675-w.
9
Cytokine Kinetics during Progression of COVID-19 in Rwanda Patients: Could IL-9/IFNγ Ratio Predict Disease Severity?卢旺达 COVID-19 患者疾病进展期间细胞因子动力学：IL-9/IFNγ 比值能否预测疾病严重程度？
Int J Mol Sci. 2023 Jul 31;24(15):12272. doi: 10.3390/ijms241512272.
10
Tissue-resident memory T cells and lung immunopathology.组织驻留记忆 T 细胞与肺部免疫病理学。
Immunol Rev. 2023 Jul;316(1):63-83. doi: 10.1111/imr.13201. Epub 2023 Apr 4.
用于治疗新冠肺炎和急性呼吸窘迫综合征患者的调节性T细胞：两例病例报告
Ann Intern Med. 2020 Nov 17;173(10):852-853. doi: 10.7326/L20-0681. Epub 2020 Jul 6.
4
Adjunct Immunotherapies for the Management of Severely Ill COVID-19 Patients.辅助免疫疗法治疗重症 COVID-19 患者。
Cell Rep Med. 2020 May 19;1(2):100016. doi: 10.1016/j.xcrm.2020.100016. Epub 2020 Apr 30.
5
Incidence of COVID-19 in a cohort of adult and paediatric patients with rheumatic diseases treated with targeted biologic and synthetic disease-modifying anti-rheumatic drugs.COVID-19 在接受靶向生物制剂和合成疾病修饰抗风湿药物治疗的成人和儿科风湿性疾病患者队列中的发病率。
Semin Arthritis Rheum. 2020 Aug;50(4):564-570. doi: 10.1016/j.semarthrit.2020.05.001. Epub 2020 May 16.
6
COVID-19 pneumonia in a large cohort of patients treated with biological and targeted synthetic antirheumatic drugs.一大群接受生物和靶向合成抗风湿药物治疗的患者中的新冠肺炎肺炎
Ann Rheum Dis. 2021 Feb;80(2):e14. doi: 10.1136/annrheumdis-2020-217681. Epub 2020 May 15.
7
High-dimensional immune profiling by mass cytometry revealed immunosuppression and dysfunction of immunity in COVID-19 patients.通过质谱流式细胞术进行的高维免疫分析揭示了COVID-19患者的免疫抑制和免疫功能障碍。
Cell Mol Immunol. 2020 Jun;17(6):650-652. doi: 10.1038/s41423-020-0447-2. Epub 2020 Apr 28.
8
The laboratory tests and host immunity of COVID-19 patients with different severity of illness.不同疾病严重程度的 COVID-19 患者的实验室检测和宿主免疫。
JCI Insight. 2020 May 21;5(10):137799. doi: 10.1172/jci.insight.137799.
9
Ongoing Clinical Trials for the Management of the COVID-19 Pandemic.正在进行的 COVID-19 大流行管理临床试验。
Trends Pharmacol Sci. 2020 Jun;41(6):363-382. doi: 10.1016/j.tips.2020.03.006. Epub 2020 Apr 9.
10
Clinical and immunological features of severe and moderate coronavirus disease 2019.新型冠状病毒病 2019 重症和中度患者的临床和免疫学特征。
J Clin Invest. 2020 May 1;130(5):2620-2629. doi: 10.1172/JCI137244.